Insmed reported 0 in Interest Income for its fiscal quarter ending in March of 2025.


Interest Income Change Date
BioMarin Pharmaceutical USD 18.83M 186K Jun/2025
Cytokinetics USD 13.7M 1.31M Mar/2025
DBV Technologies -0.32 0.02 Sep/2024
Dynavax Technologies USD 7.74M 675K Mar/2025
Gilead Sciences 73M 21M Jun/2025
Insmed 0 0 Mar/2025
Regeneron Pharmaceuticals 174.8M 1.3M Jun/2025
Sarepta Therapeutics USD 7.14M 3.05M Jun/2025
Ultragenyx Pharmaceutical USD 5.79M 1.04M Jun/2025
Vertex Pharmaceuticals USD 122.4M 1.5M Jun/2025